Document Detail

siRNA delivery: from basics to therapeutic applications.
MedLine Citation:
PMID:  23276909     Owner:  NLM     Status:  MEDLINE    
The chance to selectively intervene and stop the development of any gene-dependent disease in different organs and pathologies makes siRNA an ideal therapeutic agent. However, serious issues should be addressed before the real therapeutic use of siRNA. The poor pharmacokinetic properties of siRNA, its short half-life, its low in vivo stability, its fast elimination by kidney filtration and its low transfection efficiency complicate the use of siRNA as a therapeutic molecule. In this review, we will describe the latest and most advanced approaches and strategies undertaken to address these limitations and improve siRNA delivery and its gene silencing efficacy as well as the prospects for its therapeutic applications.
Tiziana Musacchio; Vladimir P Torchilin
Related Documents :
15869869 - Gene expression profiling of pulpal tissue reveals the molecular complexity of dental c...
20099459 - Establishment of cho cell line expressing human mchr2 gene and research of its molecula...
12682639 - Optimization of quantitative real-time rt-pcr parameters for the study of lymphoid mali...
19148599 - Quantitative gene expression analysis in kidney tissues.
20678479 - Selection and evaluation of stable housekeeping genes for gene expression normalization...
12080179 - Novel competitive pcr methods for quantitation of t-cell receptor delta (tcrd) gene rea...
22586449 - Learning transcriptional regulatory relationships using sparse graphical models.
2541559 - Transcriptional activation with concurrent or nonconcurrent template replication has di...
7618969 - Increases in nup475 and c-jun are early molecular events that precede the adaptive hype...
Publication Detail:
Type:  Journal Article; Review     Date:  2013-01-01
Journal Detail:
Title:  Frontiers in bioscience (Landmark edition)     Volume:  18     ISSN:  1093-4715     ISO Abbreviation:  Front Biosci (Landmark Ed)     Publication Date:  2013  
Date Detail:
Created Date:  2013-01-01     Completed Date:  2013-06-12     Revised Date:  2013-07-29    
Medline Journal Info:
Nlm Unique ID:  101612996     Medline TA:  Front Biosci (Landmark Ed)     Country:  United States    
Other Details:
Languages:  eng     Pagination:  58-79     Citation Subset:  IM    
Center for Pharmaceutical Biotechnology and Nanomedicine, Northeastern University, 360 Huntington Ave, Boston, MA 02115, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
DNA-Directed RNA Polymerases / metabolism
Drug Delivery Systems / methods
Drug Stability
Nanoparticles / administration & dosage
Polyethylene Glycols / administration & dosage
RNA Interference
RNA, Messenger / antagonists & inhibitors
RNA, Small Interfering / administration & dosage,  therapeutic use*
Viral Proteins / metabolism
Reg. No./Substance:
0/Micelles; 0/Polyethylene Glycols; 0/RNA, Messenger; 0/RNA, Small Interfering; 0/Viral Proteins; EC 2.7.7.-/bacteriophage T7 RNA polymerase; EC RNA Polymerases

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Steps of the coupled charge translocation in the catalytic cycle of cytochrome c oxidase.
Next Document:  Association between polymorphism of the NQO1, NOS3 and NFE2L2 genes and AMD.